Evidence map›Paper›PMID 30332452›Full record

Observational studyPloS one2018

Model of care and risk factors for poor outcomes in patients on multi-drug resistant tuberculosis treatment at two facilities in eSwatini (formerly Swaziland), 2011-2013.

M Verdecchia, K Keus, S Blankley, D Vambe, C Ssonko, T Piening, E C Casas

Abstract readObservational Study
In one paragraph

Observational study in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Survival Status and Predictors of Mortality among Multidrug-Resistant Tuberculosis Patients in Saint Peter's Specialized Hospital, Addis Ababa, Ethiopia.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2021
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

M VerdecchiaMedecins Sans Frontieres, OCA-Swaziland, Lomalanga building, Manzini, eSwatini.ORCID 0000-0002-0047-149X
K KeusMedecins Sans Frontieres, OCA-Swaziland, Lomalanga building, Manzini, eSwatini.
S BlankleyMedecins Sans Frontieres, OCA-Swaziland, Lomalanga building, Manzini, eSwatini.ORCID 0000-0001-9602-9075
D VambeNational TB control programme, Manzini, eSwatini.
C SsonkoMedecins Sans Frontieres, The Manson Unit, Lower Ground Floor, Chancery Exchange, London, United Kingdom.
T PieningMedecins Sans Frontieres, OCA-Berlin, Berlin, Germany.
E C CasasMedecins Sans Frontieres, Southern Africa Medical Unit, Observatory, Cape Town, South Africa.ORCID 0000-0003-4141-2397

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSince 2011 Médecins sans Frontières together with the eSwatini Ministry of Health have been managing patients with multi-drug resistant tuberculosis (MDR-TB) at Matsapha and Mankayane in Manzini region. This analysis describes the model of care and outcomes of patients receiving a 20 months MDR-TB treatment regimen between 2011 and 2013.

methodWe conducted a retrospective observational cohort study of MDR-TB patients enrolled for treatment between May 2011 and December 2013. An extensive package of psychological care and socio-economic incentives were provided including psychological support, paid treatment supporters, transport fees and a monthly food package. Baseline demographic details and treatment outcomes were recorded and for HIV positive patient's univariate analysis as well as a cox regression hazard model were undertaken to assess risk factors for unfavorable outcomes.

resultsFrom the 174 patients enrolled, 156 (89.7%) were HIV co-infected, 102 (58.6%) were female, median age 33 years old (IQR: 28-42), 55 (31.6%) had a BMI less than 18 and 86 (49.4%) had not been previously treated for any form of TB. Overall cohort outcomes revealed a 75.3% treatment success rate, 21.3% mortality rate, 0.6% failure and 0.6% lost to follow-up rate. In the adjusted multivariate analysis, low BMI and low CD4 count at treatment initiation were associated with an increased risk of unfavorable outcome.

conclusionsA model of care that included psychosocial support and patient's enablers led to a high level of treatment success with a very low lost to follow up rate. Limiting the overall treatment success was a high mortality rate which was associated with advanced HIV and a low BMI at presentation. These factors will need to be addressed in order to improve upon the overall treatment success rate in future.

Indexed as

Patient-Centered CareAdolescentAdultAntitubercular AgentsCoinfectionDisease ManagementEswatiniFemaleHIV InfectionsHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTreatment OutcomeTuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID30332452
PMCPMC6192624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.